Found 1 Presentation For Request "455p"
455P - Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study
- Raffaella Palumbo (Pavia, Italy)
Abstract
Background
The association of ET and CDK 4/6 inhibitors (CDK 4/6i) is the gold standard of treatment in women with HR+/HER2- MBC. The optimal therapeutic strategy after CDK 4/6i progression is still a matter of debate. The present study aimed to evaluate the benefit of the different treatments adopted in a real-world context.
Methods
In this prospective study we included women with HR+/HER2- MBC progressing to ET plus palbociclib (P). Either ET or chemotherapy (CT) were prescribed taking into account:1) site and burden of disease (visceral/plurimetastatic
Results
From May 2017 to October 2021, 78 pre- and postmenopausal patients were enrolled and 56 were evaluable for the final analysis: 18 had received ET plus P as 1st line, 38 in ≥2nd line; 22 patients were excluded because they were still on therapy at the time of the last follow-up. At progression 15 patients (26.7%) received ET (everolimus+exemestane 8, fulvestrant 7) and 41 (73.2%) were treated with CT (eribulin, capecitabine, nab-paclitaxel, vinorelbine). In the whole population mPFS1 was 17.5 months; mPFS2 was 5 months in the overall cohort (95% CI = 4-48 months) with a significant difference between ET and CT (10 months
Conclusions
In this real life experience, treatments beyond ET plus P failure provided limited but comparable clinical benefit. The physician’s choice was clearly driven by visceral burden of disease; the inflammatory status seems to have a detrimental effect on PFS2.
Clinical trial identification
Ethical Committee number 2295 approved 09.01.2017.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.